Axsome Therapeutics heads into its May 4 Q1 report as one of the more bullishly positioned CNS names in the market, with the stock up 22% over the past month and analyst targets rising in lockstep.
The analyst community is nearly unanimous in its optimism. All 16 covering analysts carry Buy-equivalent ratings, with a mean price target near $230 — implying roughly 11% upside from the current $206.53 close. The direction of travel has been consistently higher: Needham lifted its target to $255 just this week, and UBS raised to $259 back in April. That consensus has been building since February, when Wolfe Research initiated coverage with an Outperform. EPS momentum backs the bullish framing — the 30-day EPS estimate revision rank places AXSM in the 98th percentile of the universe, a signal that forecasters have been materially upgrading their near-term profit expectations heading into the print.
The lending market tells a story of minimal short pressure. Short interest runs at 5.3% of the free float — meaningful, but down roughly 6% over the past month as shorts trimmed into the rally. Borrow availability is exceptionally loose, with cost to borrow barely above 0.37% annually. The ORTEX short score has also eased, drifting from the mid-44s to 42.6 over the past two weeks. That combination — shrinking short interest, cheap borrow, and falling short score — points to a short base that is covering rather than building. There is no squeeze dynamic here; this is an orderly unwind.
Options positioning offers a mild contrasting note. The put/call ratio eased to 0.66 on Friday, just below its 20-day average of 0.68, suggesting options traders are neither aggressively bullish nor defensively positioned ahead of the event. The ratio remains well below its 52-week high of 0.82, reached just days ago — a reading that has since unwound as calls gained ground into the close.
One detail worth noting on the insider side: the recent trade log shows consistent selling across the C-suite over the past few months, including the CEO, CFO, and COO. The net 90-day insider balance amounts to roughly $19.4 million in sales. These are low-significance trades — likely routine plan-based disposals — but the pattern contrasts with the bullish external narrative. When it last reported in February, AXSM dropped 7.5% on the day and extended losses to nearly 9.5% over the following five sessions.
The May 4 print will test whether the commercial momentum behind Auvelity and the pipeline readouts can justify a stock that has re-rated sharply higher — and whether the Street's upgraded EPS expectations are finally met after a quarter that left investors disappointed.
See the live data behind this article on ORTEX.
Open AXSM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
